Lercanidipina Ciclum

Lercanidipine, the active ingredient in Lercanidipina Ciclum, is a calcium channel blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure. The drug acts by selectively inhibiting L‑type calcium channels in vascular smooth muscle, producing vasodilation and a reduction in peripheral vascular resistance.

GNH USA supplies Lercanidipina Ciclum as a licensed, GDP‑compliant international pharmaceutical product, sourced from the European Union market, and distributes it to hospitals, pharmacies and clinics worldwide.

Lercanidipine is a calcium channel blocker used to treat conditions within the hypertension disease family. - Essential hypertension: lowers systolic and diastolic blood pressure. - Primary hypertension: improves overall blood pressure control. - High blood pressure: reduces cardiovascular risk associated with sustained elevation.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warmth and redness of the skin. - Peripheral edema: swelling of the ankles or feet. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare cardiac event. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Hepatic impairment: use with caution and consider dose adjustment. - Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects. - Pregnancy and lactation: safety data are limited; prescribe only if benefits outweigh risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Grapefruit juice: can elevate drug levels and risk of hypotension. - Other potent vasodilators: may cause additive blood‑pressure reduction. - Aliskiren in diabetic patients: increased risk of renal impairment. - Simultaneous use with other calcium‑channel blockers: heightened cardiovascular effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response. - Diuretics: monitor electrolytes and blood pressure. - Beta‑blockers: observe for bradycardia. - Anticoagulants: watch for bleeding risk due to potential platelet effects.